Studies on the mechanism of antiaggregatory effect of Moutan Cortex.
The effects of Moutan Cortex and one of its major components, paeonol, on platelet aggregation and arachidonic acid (AA) metabolism in human platelets were studied. One week oral administration of water extract of Moutan Cortex [Moutan Cortex (w), 3 g/day] significantly reduced platelet aggregation and thromboxane B2 (TXB2) formation induced by collagen, epinephrine and ADP. Paeonol dose-dependently inhibited ADP and collagen induced platelet aggregation in vitro. Moutan Cortex (w) and paeonol dose-dependently inhibited the conversion of exogenous [14C]AA to [14C]heptadecatetraenoic acid [( 14C]HHT) and [14C]TXB2 by washed human platelets, while both of them increased its conversion to [14C]12-hydroxy eicosatetraenoic acid [( 14C]12-HETE). High dose of Moutan Cortex (w) inhibited the release of [14C]AA from prelabeled platelets in vitro, while paeonol did not. These results suggest that a reduction in platelet aggregation by the oral administration of Moutan Cortex might be ascribed to a decrease in thromboxane synthesis and that paeonol might play an important role in the antiaggregatory effect of Moutan Cortex because of its potent inhibitory effect on platelet aggregation and thromboxane formation.
D000098:Acetophenones / Q000494:pharmacology*; D000284:Administration, Oral; D000328:Adult; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism; D003864:Depression, Chemical; D004365:Drugs, Chinese Herbal; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D029596:Paeonia; D010936:Plant Extracts; D010946:Plants, Medicinal; D010974:Platelet Aggregation / Q000187:drug effects*; D013929:Thromboxane B2 / Q000096:biosynthesis*; D013931:Thromboxanes / Q000096:biosynthesis*
D000098:Acetophenones; D001095:Arachidonic Acids; D004365:Drugs, Chinese Herbal; D010936:Plant Extracts; D013931:Thromboxanes; C038881:moutan cortex; D016718:Arachidonic Acid; C013638:paeonol; D013929:Thromboxane B2